Rhabdoid Tumor – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022 To 2032
Rhabdoid Tumor (RT) is a rare and
aggressive pediatric soft tissue sarcoma that can arise in various body parts,
including the kidney, liver, peripheral nerves, and miscellaneous soft tissues.
RT affecting the central nervous system is referred to as Atypical Teratoid
Rhabdoid Tumor (ATRT). In most RT cases, there is biallelic inactivation of the
SMARCB1 gene, a tumor suppressor gene involved in regulating the expression of
the genome. In rare cases, RT is associated with biallelic mutations in the
SMARCA4 gene, another SWI/SNF chromatin remodeling complex member. RT commonly
occurs in infancy or childhood, with most cases occurring in patients younger
than two years old. The first symptoms are usually linked to the compressive
effects of a large tumor, such as respiratory distress, abdominal mass, or
peripheral nerve palsy. Subcutaneous nodular metastases are a specific feature
of neonatal RT cases. Diagnosis is based on imaging scans and confirmed by
biopsy and immunohistochemistry. The tumor is composed of cells with eccentric
nuclei, prominent nucleoli, and eosinophilic cytoplasm. The prognosis for RT is
poor, with a 5-year survival rate of only 20%. Factors that negatively impact
prognosis include metastases, young age at diagnosis, and incomplete resection.
ATRT is the most frequent malignant tumor of the posterior fossa in the same
age range. In infants less than one-year-old, RT may account for 20% of renal
cancers and 15% of soft-part tumors.
·
In the UK estimated age-standardized annual incidence
of extra-CNS Rhabdoid tumor is 1/2,000,000 children.
Thelansis’s “Rhabdoid Tumor Market
Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2022
To 2032" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Rhabdoid Tumor treatment modalities options
for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and
China).
KOLs insights
of Rhabdoid Tumor across 8 MM market from the centre of Excellence/ Public/
Private hospitals participated in the study. Insights around current treatment
landscape, epidemiology, clinical characteristics, future treatment paradigm,
and Unmet needs.
Rhabdoid Tumor Market Forecast Patient
Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs
with sourcing, Market Event, and Product Event, Country specific Forecast
Model, Market uptake and patient share uptake, Attribute Analysis, Analog
Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice
has been established based on a deep understanding of the pharma/biotech
business environment to provide an optimized support system to all levels of
the decision-making process. It enables business leaders in forward-thinking
and proactive decision-making. Thelansis supports scientific and commercial
teams in seamless CI support by creating an AI/ ML-based technology-driven
platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment